Measles

Pipeline Programs

Companies

Clinical Trials

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine

8100%

+ 10 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

Novo NordiskBAGSVAERD DENMARK, Denmark

3 programs

Measles vaccinePhase 4Vaccine1 trial

Active Trials

NCT00168558Completed5,879Est. Mar 2008

NCT00168571Completed1,960Est. Jan 2007

NCT00168545Completed400Est. Jan 2007

SanofiPARIS, France

1 program

Inactivated Hep A vaccine; Attenuated Measles Mumps RubellaPhase 4Vaccine1 trial

Active Trials

NCT00313950Completed470Est. Apr 2010

AP BiosciencesTaiwan - Taipei

1 program

Measles vaccinePhase 4Vaccine

Merck & Co.RAHWAY, NJ

12 programs

M-M-R™II manufactured with recombinant Human AlbuminPhase 31 trial

MMRVPhase 31 trial

Measles, Mumps, Rubella and VaricellaPhase 31 trial

ProQuad®Phase 31 trial

+7 more programs

Active Trials

NCT00962819Completed74Est. Dec 2012

NCT00986232Completed1,551Est. Sep 2000

NCT00109278Completed1,100Est. May 2005

+9 more trials

Bavarian NordicDenmark - Kvistgard

1 program

MVA-mBN85BPhase 21 trial

Active Trials

NCT00891007Completed90Est. Aug 2010

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

SanofiInactivated Hep A vaccine; Attenuated Measles Mumps Rubella

Novo NordiskMeasles vaccine

Merck & Co.MMRV

Merck & Co.ProQuad® manufactured with recombinant Human Albumin

Merck & Co.ProQuad®

Merck & Co.M-M-R™II manufactured with recombinant Human Albumin

Merck & Co.V221, measles, mumps, rubella and varicella

Merck & Co.Measles, Mumps, Rubella and Varicella

Bavarian NordicMVA-mBN85B

Merck & Co.V205C, measles, mumps, and rubella virus vaccine live

Merck & Co.measles, mumps, and rubella virus vaccine live

Showing 15 of 17 trials with date data

Clinical Trials (17)

Total enrollment: 27,351 patients across 17 trials

NCT00313950 SanofiInactivated Hep A vaccine; Attenuated Measles Mumps Rubella

Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine

Start: Sep 2006Est. completion: Apr 2010470 patients

Phase 4Completed

NCT00168545 Novo NordiskMeasles vaccine

Immunology of Non-specific Effects of Vaccine

Start: Jan 2006Est. completion: Jan 2007400 patients

Phase 4Completed

NCT00168558 Novo NordiskMeasles vaccine

Early Two-dose Measles Vaccination Trial

Start: Jul 2003Est. completion: Mar 20085,879 patients

Phase 4Completed

NCT00168571 Novo NordiskMeasles vaccine

Long-term Follow-up of Measles Antibodies

Start: Mar 2002Est. completion: Jan 20071,960 patients

Phase 4Completed

NCT01536405 Merck & Co.MMRV

Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)

Start: Jun 2012Est. completion: Jan 20141,412 patients

Phase 3Completed

NCT00566527 Merck & Co.ProQuad® manufactured with recombinant Human Albumin

Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038)

Start: Nov 2007Est. completion: Dec 20081,620 patients

Phase 3Completed

NCT00560755 Merck & Co.ProQuad®

Safety Study of ProQuad® rHA in Infants (V221-037)

Start: Oct 2007Est. completion: Nov 20083,388 patients

Phase 3Completed

NCT00402831 Merck & Co.ProQuad®

ProQuad® Intramuscular vs Subcutaneous

Start: Oct 2006Est. completion: May 2007405 patients

Phase 3Completed

NCT00432523 Merck & Co.M-M-R™II manufactured with recombinant Human Albumin

Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011)

Start: Jan 2005Est. completion: Sep 2005752 patients

Phase 3Completed

NCT00092430 Merck & Co.V221, measles, mumps, rubella and varicella

Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)

Start: Sep 2002Est. completion: Jun 20031,200 patients

Phase 3Completed

NCT00984295 Merck & Co.Measles, Mumps, Rubella and Varicella

Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines

Start: Jun 2000Est. completion: Dec 20011,913 patients

Phase 3Completed

NCT00985153 Merck & Co.Measles, Mumps, Rubella and Varicella

Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED)

Start: Mar 2000Est. completion: May 20013,927 patients

Phase 3Completed

NCT00891007 Bavarian NordicMVA-mBN85B

Study to Evaluate Safety, Dose Response and Immunogenicity of the Measles Vaccine MVA mBN85B in Healthy Children Aged 6 Months to 6 Years

Start: Jun 2009Est. completion: Aug 201090 patients

Phase 2Completed

NCT00109278 Merck & Co.V205C, measles, mumps, and rubella virus vaccine live

A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED)

Start: Oct 2004Est. completion: May 20051,100 patients

Phase 2Completed

NCT00092404 Merck & Co.measles, mumps, and rubella virus vaccine live

Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED)

Start: Dec 2001Est. completion: Jun 20051,210 patients

Phase 2Completed

NCT00986232 Merck & Co.Measles, Mumps, Rubella and Varicella

ProQuad Dose Selection Study (V221-011)(COMPLETED)

Start: Apr 1999Est. completion: Sep 20001,551 patients

Phase 2Completed

NCT00962819 Merck & Co.MMR vaccine

Measles, Mumps, and Rubella (MMR) Immunity in College Students

Start: Mar 2010Est. completion: Dec 201274 patients

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

8 late-stage (Phase 3) programs — potential near-term approvals

5 companies competing in this space